Pharmaceuticals

GSK acquires Elsie Biotechnologies for $50 million to strengthen oligonucleotide pipeline

bexib
By bexib 0 Min Read

The acquisition of Elsie Biotechnologies is expected to strengthen GSK’s research capabilities in modulating gene expression through the use of oligonucleotides.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article How to Find the Best Time to Post on TikTok in 2024
Next Article Wheat market fundamentals should drive prices higher in the medium term – RealAgriculture
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Ben Wong heads Adyen’s Southeast Asia and Hong Kong operations
Fintech
Moving towards retention: Planday reveals actionable insights to reduce hospitality staff turnover
Hospitality & Tourism
New CDC Respiratory Virus “Community Snapshot Caves to Covid Minimizers, Deceives Those Who Want to Stay Safe
Economy
My weekly reading for October 6, 2024
Economy